Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078064 | 0.88 | F2 (0.47) | POLBEGFRSPHK1 | |
| SCHEMBL6077686 | 0.84 | MAOA (0.45) | MAOAMAOBGRM2SCN3APOLB | |
| SCHEMBL6077730 | 0.82 | F2 (0.39) | EGFRIDO1TDO2ALDH1A1 | |
| SCHEMBL6920324 | 0.76 | TSHR (0.40) | — | |
| SCHEMBL6078513 | 0.74 | AAK1 (0.38) | POLB | |
| SCHEMBL6078268 | 0.73 | F2 (0.45) | — | |
| SCHEMBL6919450 | 0.72 | MAOB (0.44) | MAOAMAOB | |
| SCHEMBL6914971 | 0.72 | MAOB (0.44) | MAOAMAOB | |
| SCHEMBL29586935 | 0.72 | SCN3A (0.49) | MAOAMAOBGRM2SCN3APOLB | |
| SCHEMBL6078656 | 0.71 | F2 (0.47) | POLBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | MAOA 2066/4885MAOB 1593/4885GRM2 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.